Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II)
- PMID: 1606787
- DOI: 10.2165/00003088-199222040-00003
Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II)
Abstract
Positron emission tomography (PET) involves imaging the biodistribution and tissue localisation of small amounts of radiolabelled biomolecules or drugs. In Part I of this article, which appeared in the previous issue of the Journal, the applications of pharmacokinetics in PET were discussed in order to derive quantitative measures of physiological function. Part II examines the use of PET imaging as a tool to study the pharmacokinetics and pharmacodynamics of specific drugs.
Similar articles
-
Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part I).Clin Pharmacokinet. 1992 Mar;22(3):211-22. doi: 10.2165/00003088-199222030-00003. Clin Pharmacokinet. 1992. PMID: 1559312 Review.
-
[Positron emission tomography in pharmacokinetics and pharmacodynamics].Boll Chim Farm. 1993 Jul-Aug;132(7):231-3. Boll Chim Farm. 1993. PMID: 8398055 Review. Italian.
-
Small-animal PET: a promising, non-invasive tool in pre-clinical research.Eur J Pharm Biopharm. 2010 Jan;74(1):50-4. doi: 10.1016/j.ejpb.2009.05.012. Epub 2009 May 29. Eur J Pharm Biopharm. 2010. PMID: 19482080
-
Positron emission tomography in drug development.Q J Nucl Med. 1997 Jun;41(2):171-5. Q J Nucl Med. 1997. PMID: 9203856
-
Molecular imaging of cancer with positron emission tomography.Nat Rev Cancer. 2002 Sep;2(9):683-93. doi: 10.1038/nrc882. Nat Rev Cancer. 2002. PMID: 12209157 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources